BRD4通过SHH信号通路诱导甲状腺癌细胞增殖、侵袭与迁移

doi:10.19401/j.cnki.1007-3639.2017.11.004

中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (11): 860-866.doi: 10.19401/j.cnki.1007-3639.2017.11.004

BRD4通过SHH信号通路诱导甲状腺癌细胞增殖、侵袭与迁移

冀凯伦¹，刘　琪²，牟作峰²，马晓东²，李国楼²

1. 潍坊医学院临床学院，山东潍坊 261053 ；
2. 潍坊市中医院乳腺甲状腺外科，山东潍坊 261041

出版日期:2017-11-30 发布日期:2017-12-12
通信作者: 李国楼　E-mail：guolouli@sina.com
基金资助:
潍坊市卫生局科研立项项目(2015WS006)。

BRD4 induces proliferation, invasion and migration of thyroid cancer cells via SHH signaling pathway

JI Kailun¹, LIU Qi², MU Zuofeng², MA Xiaodong², LI Guolou²

1. Clinical College of Weifang Medical University, Weifang 261053, Shandong Province, China; 2. Department of Breast and Thyroid Surgery, the Traditional Chinese Medicine Hospital of Weifang, Weifang 261041, Shandong Province, China

Published:2017-11-30 Online:2017-12-12
Contact: LI Guolou E-mail: guolouli@sina.com

摘要/Abstract

摘要： 背景与目的：甲状腺癌是目前发病率最高的内分泌系统恶性肿瘤之一，目前的综合治疗手段虽然效果较好，但是部分患者在随后的治疗中会出现继发性摄碘率下降，¹³¹I治疗效果差，从而导致复发及远处转移。近年来的研究发现，溴样结构域蛋白4(double bromodomain-containing protein 4，BRD4)可促进多种恶性肿瘤的进展，因此本研究旨在探究BRD4在甲状腺乳头状癌(papillary thyroid cancer，PTC)细胞中的作用，寻找治疗甲状腺癌的特异性靶点。方法：应用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR)检测PTC组织和癌周组织中BRD4的表达差异，应用siBRD4干扰基因转染PTC细胞株TPC-1，应用蛋白［质］印迹法(Western blot)检验沉默效果，通过MTT实验、平板克隆实验、Transwell小室侵袭与迁移实验检验沉默BRD4前后PTC细胞株TPC-1活力、增殖、迁移及侵袭等生物学行为的变化。进一步应用Western blot及RTFQ-PCR检测钠碘转运体(sodium iodide symporter，NIS)基因及蛋白的表达变化，以及SHH信号通路下游基因SHH、GLI1表达变化情况。结果：BRD4在PTC组织中表达明显增高(P＜0.05)；在体外实验中BRD4沉默后PTC细胞株TPC-1的细胞活力、增殖、迁移与侵袭能力下降。此外，BRD4沉默后NIS基因及蛋白表达增高，SHH信号通路下游基因SHH、GLI1表达降低(P＜0.05)。结论：BRD4通过上调SHH信号通路相关基因促进PTC细胞的侵袭与迁移，沉默BRD4可以促进NIS的表达，BRD4有望成为治疗甲状腺癌的新靶点。

关键词: 甲状腺癌, 溴样结构域蛋白4, SHH信号通路, 钠碘转运体基因

Abstract: Background and purpose: Thyroid cancer is the endocrine malignant tumor with the highest incidence. Although comprehensive treatment has gotten considerable effect, some patients have low iodine uptake and poor ¹³¹I therapeutic effect in the subsequent treatment which causes recurrence and distant metastasis. Recent studies have found that double bromodomain-containing protein 4 (BRD4) plays a key role in promoting the progression of some malignant tumors. Therefore, we aimed to investigate the effect of BRD4 in papillary thyroid cancer (PTC), and search for the specific target of thyroid cancer. Methods: Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to examine the BRD4 expression in PTC tissue and para-cancerous tissue. PTC cell line TPC-1 was transfected with the siBRD4. And then the silence efficiency was examined by Western blot. The effects of BRD4 on cell viability, proliferation, migration and invasion were examined by MTT assay, colony formation assay and transwell assay. Besides, Western blot and RTFQ-PCR were used to examine the expression of sodium iodide symporter (NIS) and the downstream gene SHH and GLI1 of SHH signaling pathway. Results: BRD4 was overexpressed in PTC tissue (P<0.05). In vitro experiment showed that the viability, proliferation, invasion and migration of BRD4-silencing cells were decreased. Besides, the mRNA and protein expression levels of NIS were up-regulated while the downstream gene of SHH signaling pathway SHH and GLI1 were down-regulated (P<0.05). Conclusion: BRD4 would promote the invasion and migration of papillary thyroid cancer cells via up-regulating the genes of SHH signaling pathway. Silencing BRD4 can promote the expression of NIS. BRD4 may be a new target for the treatment of thyroid cancer.

Key words: Thyroid cancer, Double bromodomain-containing protein 4, SHH signaling pathway, Sodium iodide symporter gene

冀凯伦,刘　琪,牟作峰,等. BRD4通过SHH信号通路诱导甲状腺癌细胞增殖、侵袭与迁移[J]. 中国癌症杂志, 2017, 27(11): 860-866.

JI Kailun, LIU Qi, MU Zuofeng, et al. BRD4 induces proliferation, invasion and migration of thyroid cancer cells via SHH signaling pathway[J]. China Oncology, 2017, 27(11): 860-866.

[1]	袁　浩, 蒋晓飞, 游庆华, 朱红波, 叶慧英, 伍　雯, 钱丰源, 钟　明, 李永平 . 甲状旁腺细针穿刺Diff-Quik染色在甲状腺癌手术中的临床应用[J]. 中国癌症杂志, 2021, 31(4): 302-307.
[2]	张婷婷, 王蕴珺, 渠　宁, 孙团起. 30例胸腺样分化甲状腺癌的回顾性分析及其机制研究[J]. 中国癌症杂志, 2021, 31(11): 1058-1062.
[3]	武鸿文, 梅　艳, 王　乔, 袁　佳, 赵立威. 血清MIP-1α、S-TK1对于甲状腺癌术后放射性 ¹³¹ I治疗效果评估的临床价值[J]. 中国癌症杂志, 2021, 31(11): 1088-1095.
[4]	程　玉, 郝美玲, 薛　晶, 齐洁敏 . 节律因子BMAL1通过SHH信号转导通路影响胃癌MGC-803细胞的增殖[J]. 中国癌症杂志, 2020, 30(9): 661-666.
[5]	李　敏, 文　鹏, 钱秋琴, 秦　昂, 曾　理, 石　峰. 碘-125粒子植入治疗碘难治性分化型甲状腺癌淋巴结转移灶的临床研究[J]. 中国癌症杂志, 2020, 30(2): 122-127.
[6]	杨　珂，郑　容，林岩松. 儿童青少年甲状腺癌诊治指南解读及其进展——核医学部分[J]. 中国癌症杂志, 2019, 29(6): 401-411.
[7]	张立阳，刘春浩，曹　越，刘洪沨，高维生，李小毅. 125例复发/持续性分化型甲状腺癌再次手术及其预后影响因素分析[J]. 中国癌症杂志, 2019, 29(6): 412-417.
[8]	高璐滢，林岩松，姜玉新，李建初，李慧，张波，刘如玉，席雪华，高琼，王莹，赵瑞娜. 颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效[J]. 中国癌症杂志, 2019, 29(6): 418-422.
[9]	眭慧敏，刘杰蕊，王瞳，朱朝晖，林岩松. 儿童及青少年分化型甲状腺癌远处转移的临床病理学危险因素分析[J]. 中国癌症杂志, 2019, 29(6): 423-428.
[10]	卢承慧，李娇，刘新峰，王国强，王增华，王叙馥. 治疗前刺激性甲状腺球蛋白阴性合并淋巴结转移的分化型甲状腺癌¹³¹I治疗后的临床转归[J]. 中国癌症杂志, 2019, 29(6): 429-433.
[11]	项洋锋，郑传铭，葛明华. 无充气耳后发际入路完全腔镜下甲状腺癌根治术效果初探[J]. 中国癌症杂志, 2019, 29(6): 434-438.
[12]	张娜，林岩松，梁军. 甲状腺球蛋白抗体测定在分化型甲状腺癌¹³¹I治疗中的临床意义[J]. 中国癌症杂志, 2019, 29(6): 452-456.
[13]	中国临床肿瘤学会（CSCO）甲状腺癌专家委员会中国研究型医院学会甲状腺疾病专业委员会中国医师协会外科医师分会甲状腺外科医师委员会医促会甲状腺疾病专业委员会. 碘难治性分化型甲状腺癌的诊治管理共识（2019年版）[J]. 中国癌症杂志, 2019, 29(6): 476-480.
[14]	陈俊慧，张　曼，刘水澎，马　琳，刘　洋，李晓松，孟　健，李　劼，张树华. 基于超声征象多因素logistic回归β值积分法的甲状腺癌风险预测研究[J]. 中国癌症杂志, 2019, 29(4): 289-293.
[15]	宋娟娟，刘延晴，林岩松. 中低危分化型甲状腺癌低剂量¹³¹I治疗后短期转归的临床分析[J]. 中国癌症杂志, 2019, 29(3): 207-211.

BRD4通过SHH信号通路诱导甲状腺癌细胞增殖、侵袭与迁移

BRD4 induces proliferation, invasion and migration of thyroid cancer cells via SHH signaling pathway

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价